Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial

Overview of attention for article published in Respiratory Research, April 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 38 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,270 followers.

@KerriBerriKerri @c_kawala @shapps999 @jolenehfisher @Paulwnoblemd @TobyMMaher @scott_matson @ILDIPFDoc_NI @PilarRiveraOrt1 Yes, same here, Kerri. Also cautious about its use in pts with CAD on high-dose antiplatelet therapy or full-dose therapeutic antic

Reply Repost Favourite

RT @RespiratoryBMC: New article: Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: d…

Reply Repost Favourite

New article: Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial https://t.co/DYniFmRQhB

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.